JP7677953B2 - 前立腺癌処置のための免疫治療薬 - Google Patents

前立腺癌処置のための免疫治療薬 Download PDF

Info

Publication number
JP7677953B2
JP7677953B2 JP2022516126A JP2022516126A JP7677953B2 JP 7677953 B2 JP7677953 B2 JP 7677953B2 JP 2022516126 A JP2022516126 A JP 2022516126A JP 2022516126 A JP2022516126 A JP 2022516126A JP 7677953 B2 JP7677953 B2 JP 7677953B2
Authority
JP
Japan
Prior art keywords
gnrh
seq
peptide
oligomer
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548050A5 (https=
JP2022548050A (ja
Inventor
キース・ダグラス・ミラー
ロバート・ボグデン
Original Assignee
ヘキサマー・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘキサマー・セラピューティクス・インコーポレイテッド filed Critical ヘキサマー・セラピューティクス・インコーポレイテッド
Publication of JP2022548050A publication Critical patent/JP2022548050A/ja
Publication of JP2022548050A5 publication Critical patent/JP2022548050A5/ja
Priority to JP2025076282A priority Critical patent/JP2025124645A/ja
Application granted granted Critical
Publication of JP7677953B2 publication Critical patent/JP7677953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022516126A 2019-09-12 2020-09-10 前立腺癌処置のための免疫治療薬 Active JP7677953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076282A JP2025124645A (ja) 2019-09-12 2025-05-01 前立腺癌処置のための免疫治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899553P 2019-09-12 2019-09-12
US62/899,553 2019-09-12
PCT/US2020/050194 WO2021050722A1 (en) 2019-09-12 2020-09-10 An immunotherapeutic for prostate cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076282A Division JP2025124645A (ja) 2019-09-12 2025-05-01 前立腺癌処置のための免疫治療薬

Publications (3)

Publication Number Publication Date
JP2022548050A JP2022548050A (ja) 2022-11-16
JP2022548050A5 JP2022548050A5 (https=) 2023-09-14
JP7677953B2 true JP7677953B2 (ja) 2025-05-15

Family

ID=74867215

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516126A Active JP7677953B2 (ja) 2019-09-12 2020-09-10 前立腺癌処置のための免疫治療薬
JP2025076282A Pending JP2025124645A (ja) 2019-09-12 2025-05-01 前立腺癌処置のための免疫治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076282A Pending JP2025124645A (ja) 2019-09-12 2025-05-01 前立腺癌処置のための免疫治療薬

Country Status (10)

Country Link
US (1) US20220339238A1 (https=)
EP (2) EP4028043A4 (https=)
JP (2) JP7677953B2 (https=)
KR (1) KR20220062080A (https=)
CN (1) CN114599387A (https=)
AU (1) AU2020346818A1 (https=)
BR (1) BR112022004477A2 (https=)
CA (1) CA3152055A1 (https=)
MX (1) MX2022003100A (https=)
WO (1) WO2021050722A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025124645A (ja) * 2019-09-12 2025-08-26 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法
JP7837616B2 (ja) * 2025-07-25 2026-03-31 株式会社大都技研 遊技台

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504151A (ja) 2008-09-30 2012-02-16 セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア ゴナドトロピン放出ホルモン（ｇｎｒｈ）変異体の組合せを免疫原として使用する医薬組成物
US20170049883A1 (en) 2014-04-25 2017-02-23 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
WO1997015316A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
AU2016419048B2 (en) * 2016-08-11 2024-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
MA52591A (fr) * 2018-07-12 2021-06-02 Hexamer Therapeutics Inc Échafaudage peptidique autoassemblé
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504151A (ja) 2008-09-30 2012-02-16 セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア ゴナドトロピン放出ホルモン（ｇｎｒｈ）変異体の組合せを免疫原として使用する医薬組成物
US20170049883A1 (en) 2014-04-25 2017-02-23 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Epitope targeting with self-assembled peptide vaccines，Npj Vaccines，2019年07月19日，Vol.4, Article No.30，p.1-8
Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier，PLOS One，2014年，Vol.9, No.12, e114366，p.1-19

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025124645A (ja) * 2019-09-12 2025-08-26 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬

Also Published As

Publication number Publication date
BR112022004477A2 (pt) 2022-05-31
JP2025124645A (ja) 2025-08-26
CN114599387A (zh) 2022-06-07
WO2021050722A1 (en) 2021-03-18
CA3152055A1 (en) 2021-03-18
EP4028043A1 (en) 2022-07-20
EP4028043A4 (en) 2023-08-02
EP4183417A1 (en) 2023-05-24
US20220339238A1 (en) 2022-10-27
MX2022003100A (es) 2022-04-06
JP2022548050A (ja) 2022-11-16
KR20220062080A (ko) 2022-05-13
AU2020346818A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7677953B2 (ja) 前立腺癌処置のための免疫治療薬
KR101240547B1 (ko) Ｔ-헬퍼 및 ｂ-세포 에피토프를 포함하는 신규한 면역원성리포펩타이드
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
US20230218748A1 (en) Artificial promiscuous t helper cell epitopes as immune stimulators for synthetic peptide immunogens
US20260061049A1 (en) Self-assembling peptide scaffold
CN113574073A (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
US20230346920A1 (en) Vaccines against viral pathogens
RU2839585C2 (ru) Искусственные неизбирательные эпитопы клеток т-хелперов как иммунные стимуляторы для синтетических пептидных иммуногенов
WO2016029013A2 (en) Methods for improving immunological response in vaccinated animals

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230906

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250501

R150 Certificate of patent or registration of utility model

Ref document number: 7677953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150